Luvox vs Fluoxetine: Sexual Side Effects Comparison
Based on the available evidence, fluvoxamine (Luvox) appears to have fewer sexual side effects compared to fluoxetine (Prozac), though both SSRIs carry significant risk for sexual dysfunction.
Key Evidence from Guidelines
The American College of Physicians guidelines directly address this comparison, stating that paroxetine had higher rates of sexual dysfunction than fluoxetine, fluvoxamine, nefazodone, or sertraline 1. This indicates fluvoxamine ranks among the SSRIs with relatively lower sexual dysfunction rates compared to some alternatives, and specifically lower than paroxetine but in a similar range to fluoxetine 1.
Head-to-Head Research Data
Comparative Incidence Rates
The most relevant prospective multicenter study provides specific incidence data 2:
- Fluvoxamine: 62.3% (48/77 patients)
- Fluoxetine: 57.7% (161/279 patients)
This suggests fluvoxamine may actually have slightly higher sexual dysfunction rates than fluoxetine, though the difference is modest (approximately 5% absolute difference) 2.
Another prospective study found 3:
- Both medications caused sexual dysfunction in the majority of patients
- Paroxetine caused significantly more orgasm/ejaculation delay and impotence than both fluvoxamine and fluoxetine (p < 0.05) 3
- This places fluvoxamine and fluoxetine in a similar, intermediate category
Clinical Significance
A 2006 review specifically noted that fluvoxamine may have fewer effects on sexual dysfunction compared to other SSRIs 4. However, observational cohort studies found fluvoxamine had a higher overall incidence of adverse events compared to fluoxetine, sertraline, and paroxetine, though sexual dysfunction specifically was not the primary driver 5.
FDA Label Information
The Luvox FDA label acknowledges that sexual dysfunction rates are likely underreported and lists common sexual side effects including 6:
- Abnormal ejaculation (mostly delayed ejaculation)
- Anorgasmia (particularly in males)
- Decreased libido
- Impotence
The label emphasizes these occur at rates requiring routine physician inquiry 6.
Clinical Algorithm for Selection
When sexual function is a primary concern:
First consideration: Both medications carry 58-62% risk of sexual dysfunction 2
Relative ranking among SSRIs (lowest to highest sexual dysfunction) 1, 2:
- Bupropion (non-SSRI, significantly lower)
- Nefazodone, mirtazapine (8-24%)
- Sertraline, fluoxetine, fluvoxamine (58-62%)
- Paroxetine (71%)
Practical decision: The difference between fluvoxamine and fluoxetine is clinically marginal (approximately 5% absolute difference), making them essentially equivalent choices when sexual side effects are the primary concern 2, 3
Important Caveats
- Sexual dysfunction severity: Men experience higher frequency but women report greater severity 2, 3
- Dose-dependent effect: Sexual dysfunction correlates positively with dose for both medications 3
- Persistence: In 81.4% of patients, sexual dysfunction showed no improvement after 6 months of continued treatment 3
- Underreporting: Spontaneous reporting captures only 14% of cases versus 58% when directly questioned 3
Bottom Line
Neither medication offers a clear advantage over the other regarding sexual side effects—both carry approximately 58-62% risk. If sexual function preservation is critical, consider non-SSRI alternatives like bupropion (significantly lower sexual dysfunction rates) or mirtazapine/nefazodone 1, 2. When choosing between fluvoxamine and fluoxetine specifically, base the decision on other factors such as drug interactions, cost, or other side effect profiles rather than sexual dysfunction risk, as they are essentially equivalent in this domain 1, 2, 3.